INDICATES – INDIvidualized loCAl Therapy for patients with Ewing Sarcoma: a new clinical prediction tool

Title

Code

INDICATES

Type

Osservazionale

Start Year

2025

Status

In Corso

Principal Investigator

051-6366267

giuseppe.bianchi@ior.it

Bianchi Giuseppe, MD

3rd Orthopaedic and Traumatologic Clinic prevalently Oncologic

Operational unit that carry out the study

complex unit

Clinica Ortopedica e Traumatologica III a prevalente indirizzo Oncologico

Director

Donati Davide Maria, MD

Go to the details >>

Documents and Videos attachament

Attachment

Nulla osta alla conduzione dello studio prot. INDICATES

Monday 20 January 2025, 15:46

PG0000032_2025_Stampa_unica.pdf

You might also be interested in

Clinical Trial

A Phase 2/3, Randomized, Multicenter Study to Evaluate AL102 in Patients with Progressing Desmoid Tumors

Clinical Trial

Phase study 1/2 to evaluate palbociclib (IBRANCE®) in combination with irinotecan and temozolomide or in combination with topotecan and cyclophosphamide in pediatric patients with recurrent orrefractory solid tumors

IRCCS

ISTITUTO ORTOPEDICO RIZZOLI

INDICATES – INDIvidualized loCAl Therapy for patients with Ewing Sarcoma: a new clinical prediction tool

Principal Investigator

Operational unit that carry out the study

Documents and Videos attachament

You might also be interested in

Sito Web Istituto Ortopedico Rizzoli

INDICATES – INDIvidualized loCAl Therapy for patients with Ewing Sarcoma: a new clinical prediction tool

Principal Investigator

Operational unit that carry out the study

Documents and Videos attachament

You might also be interested in